CureVac
Ursula Biedinger has over 30 years of experience in project management and research within the pharmaceutical and flavor industries. Currently serving as the Director of Program Management for Molecular Therapy at CureVac AG since January 2018, Ursula previously held the position of Senior Project Manager in R&D at Mundipharma Germany GmbH & Co. KG from June 2016 to January 2018. Prior to that, Ursula was the Head of Phase I-II Project Management and Clinical Trial & Portfolio Manager at Biotrial from February 2006 to May 2016. Ursula's earlier career includes roles as a medical/technical translator and quality control head in the flavor and fragrance industry, as well as various positions in research and international relations.
This person is not in any teams
CureVac
8 followers
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases.